[1] ARNOLD M, SIERRA M S,LAVERSANNE M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J].Gut,2017,66:683-691. [2] SCHREUDERS E H, RUCO A, RABENECK L,et al. Colorectal cancer screening:a global overview of existing programmes[J]. Gut, 2015, 64(10):1637-1649. [3] LINNEKAMP J F,WANG X, MEDEMA J P,et al.Colorectal cancer heterogeneity and targeted therapy:a case for molecular disease subtypes[J]. Cancer Res, 2015,75(2):245-249. [4] LIU Y, YIN H, ZHAO M, et al. TLR2 and TLR4 in autoimmune diseases:a comprehensive review[J]. Clin Rev Allergy Immunol, 2014, 47(2):136-147. [5] LIU Y D, JI C B, LI S B, et al. Toll-like receptor 2 stimulation promotes colorectal cancer cell growth via PI3K/Akt and NF-κB signaling pathways[J]. Int Immunopharmacol, 2018, 9:375-383. [6] LU C C, KUO H C, WANG F S, et al. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer[J]. Int J Mol Sci, 2015, 16(1):159-177. [7] MEDVEDEV A E. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer[J]. J Interferon Cytokine Res, 2013,33(9):467-484. [8] HERNANDEZ C, HUEBENER P, SCHWABE R F. Damage-associated molecular patterns in cancer:a double-edged sword[J]. Oncogene, 2016, 35(46):5931-5941. [9] PROENCA M A, DE OLIVEIRA J G, CADAMURO A C, et al. TLR2 and TLR4 polymorphisms influence mRNA and protein expression in colorectal cancer[J]. World J Gastroenterol, 2015, 21(25):7730-7741. [10] KENNEDY C L, NAJDOVSKA M, TYE H, et al. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis[J]. Oncogenes, 2014, 33(19):2540-2546. [11] WEST A C, TANG K,TYE H, et al. Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer[J]. Oncogenes, 2017, 36(36):5134-5144. [12] GRIMMIG T, MOENCH R, KRECKEL J, et al. Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and VEGF/PDGF expression in human pancreatic cancer[J]. Int J Mol Sci, 2016, 17(12):e2060. [13] SCHEEREN F A, KUO A H, et al. A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis[J]. Nat Cell Biol, 2014, 16(12):1238-1248. [14] MASTORCI K, MURARARO E, PASINI E, et al. Toll-like receptor 1/2 and 5 ligands enhance the expression of cyclin D1 and D3 and induce proliferation in mantle cell lymphoma[J]. PLoS One, 2016, 11(4):e0153823. [15] LI X T, QIAN D M, JU F, et al. Upregulation of Toll-like receptor 2 expression in colorectal cancer infected by human cytomegalovirus[J]. Oncol Lett, 2015, 9(1):365-370. [16] GUO H, CHEN Y, HU X, et al.The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells[J]. Mol Cancer, 2013, 12:77. [17] WANG M J, PING J,LI Y, et al. Prognostic significance and molecular features of colorectal mucinous adenocarcinomas:a strobe-compliant study[J]. Medicine (Baltimore), 2015,94(51):e2350. [18] SEMLALI A, REDDY P N, ARAFAH M, et al. Expression and polymorphism of Toll-like receptor 4 and effect on NF-κB mediated inflammation in colon cancer patients[J]. PLoS One, 2016,11(1):e0146333. [19] GUTTRIDGE D C, ALBANESE C, REUTHER J Y, et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1[J]. Mol Cell Biol, 1999, 19(8):5785-5799. [20] WILLIAMS G H, STOECER K. The cell cycle and cancer[J]. J Pathol, 2012, 226(2):352-364. [21] LIU Y Y, FAN C H, PU L, et al. Phloretin induces cell cycle arrest and apoptosis of human glioblastoma cells through the generation of reactive oxygen species[J]. J Neurooncol,2016,128(2):217-223. |